{"success":true,"data":{"pressRelease":{"id":"39177","rtpr_id":"nGNE5Prrnj","ticker":"NXL","exchange":"NASDAQ","all_tickers":["NXL"],"title":"Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial","author":"Globe Newswire","published_at":"2026-05-19T12:30:00.365Z","article_body":"Acquisition gives Nexalin control of AI-integrated remote patient-monitoring,\nclinical data-capture and virtual-care infrastructure already deployed at UCSD\n\nHOUSTON, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc.\n(https://www.globenewswire.com/Tracker?data=HF4Wy7GwqwKbBEYDet4v36q8CzvC_i2u9qmSx0gRP3JNhjHZN7NoWdxsKzJ_ZeJfQMx1iVUpULWj1Am2xNRUBiDtGuXABQqgW5FGO81otzw7NAqhES0Y-UpPS10DYzaCr5ii1vU0Zx9vg4rlLEg0KsQ7gf7Q4JLgG12z7u_6tGLlRiLGfKWPHhnaU5uLZ45YI9u3Q_2MD58Y3Flir6SEWFGPqUDVqx6HC05naOjMY_Iwcsz3ciMmH8DnFTIauQHbygx--iA2vjX_y-amLhB2w1WTzo6aszqokHOsrRAxIus=)\n( (Nasdaq: NXL) (“Nexalin” or the “Company”), the leader in\nnon-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain,\ntoday announced the closing of its acquisition of PONM, Inc. (“PONM”) from\nGreenLight Ventures, LLC (“GreenLight”). PONM is the digital health\nplatform supporting Nexalin’s HALO™ Clarity program and Nexalin\nNeuroCare™ virtual clinic.\n\nThrough the transaction, Nexalin has secured ownership of PONM and an\nexclusive license to the proprietary software features developed for the\nHALO™ program, including AI-integrated remote patient monitoring,\ntreatment-compliance data capture, electronic health record functionality,\nvirtual-clinic management, real-time clinical-data analysis and analytics\ncapabilities. The technology is already deployed at the University of\nCalifornia, San Diego (“UCSD”), where it supports HALO™ headset usage\ntracking, remote prescribing, physician oversight and clinical research\nworkflows.\n\nThe acquisition gives Nexalin greater control over a critical layer of its\nHALO™ Clarity ecosystem: the digital infrastructure that connects the\ndevice, the patient, the prescribing physician and the clinical-data workflow.\nNexalin believes this integrated device-plus-software model is important to\nthe Company’s planned pivotal trial, future regulatory strategy and\npotential commercial deployment of HALO™ Clarity as an at-home,\nphysician-supervised therapy. The platform is designed to use AI-enabled tools\nto support real-time data capture, treatment-adherence monitoring, protocol\ncompliance and physician oversight across clinical research and future\npatient-management workflows.\n\nAt UCSD, phases one through five of the Nexalin NeuroCare™ virtual clinic\nhave been deployed to support patient recruitment, AI-integrated monitoring\nand clinical-data workflows for Nexalin’s TBI/PTSD military study, and are\nbeing readied to support the Company’s planned 160-participant FDA pivotal\ntrial of HALO™ Clarity for moderate-to-severe insomnia, with enrollment\nexpected to begin in Q2 2026.\n\nIn connection with the transaction, GreenLight has become a meaningful equity\nholder in Nexalin, aligning the parties around the long-term success of\nHALO™ Clarity, Nexalin NeuroCare™ and the Company’s broader\nneurostimulation platform.\n\nAs part of the broader transaction structure, Nexalin and GreenLight have\nentered into a strategic partnership that provides Nexalin with continued\naccess to GreenLight’s product, engineering, quality assurance,\ncybersecurity, regulatory, behavioral-health and commercial-development\ncapabilities.\n\n“This acquisition gives Nexalin ownership of a critical part of the HALO™\nClarity ecosystem: the digital platform that connects the device, the patient,\nthe physician and the clinical-data workflow,” said Mark White, Chief\nExecutive Officer of Nexalin Technology. “The PONM platform is already\ndeployed at UCSD and supports the AI-integrated remote-monitoring,\nclinical-data capture and virtual-clinic capabilities we believe are essential\nto scaling HALO™ Clarity. By bringing this infrastructure under Nexalin\nownership, we are strengthening our ability to execute through pivotal trial\nactivities, planned FDA submission and potential commercial launch. We believe\ncombining HALO™ Clarity with AI-enabled data infrastructure can strengthen\ntreatment oversight, improve protocol adherence and create a scalable\nfoundation for future physician-supervised, at-home neurostimulation\nprograms.”\n\n“We believe the future of neurostimulation will be defined not only by the\ndevice itself, but by the software, data and physician-supervised care model\naround it,” continued Mr. White. “This transaction strengthens Nexalin’s\ncontrol over that full ecosystem and expands what we believe the Company can\nultimately offer to patients and providers seeking non-invasive treatment\nalternatives.”\n\n“GreenLight has spent years building digital infrastructure for\nnext-generation healthcare technologies, and HALO™ Clarity is exactly the\ntype of platform our work was designed to support,” said Peter Gratale,\nFounder of GreenLight Ventures. “With this transaction, Nexalin has the\nexclusive rights to the platform, while GreenLight remains aligned as both a\nlong-term partner and shareholder. Under our strategic partnership,\nGreenLight’s broader product, engineering, regulatory, clinical and\ncommercial capabilities will remain available to support HALO™ Clarity\nthrough pivotal trial execution, regulatory submission and potential\ncommercial launch.”\n\nTotal consideration for the transaction is $1.3 million, payable in shares of\nNexalin common stock issued in tranches over time at prices tied to\nNexalin’s market performance. Nexalin believes this structure aligns\nGreenLight’s economics with the long-term success of the HALO™ Clarity and\nNexalin NeuroCare™ programs.\n\nNexalin believes the transaction strengthens its ability to integrate device,\nsoftware, AI-enabled remote monitoring and clinical-data infrastructure under\na unified platform designed to support HALO™ Clarity through clinical\ndevelopment, regulatory submission and planned commercialization.\n\nAbout Nexalin Technology, Inc.\n\nNexalin designs and develops innovative neurostimulation products to uniquely\nhelp combat the ongoing global mental health epidemic. Nexalin’s medical\ndevices are non-invasive and undetectable to the human body. Nexalin believes\nits neurostimulation medical devices can penetrate structures deep in the\nmid-brain that are associated with mental health disorders, and that the\ndeeper-penetrating waveform in its next-generation devices, including the\nHALO™ Clarity, will generate enhanced patient response without adverse side\neffects. The Nexalin Gen-2 SYNC 15 milliamp neurostimulation device has been\napproved in China, Brazil, Oman, and Israel. Additional information is\navailable at www.nexalin.com.\n\nAbout PONM\n\nPONM is a digital health platform built to power next-generation healthcare\ntechnologies. Its software supports clinical data capture, remote patient\nmonitoring, electronic health records, telehealth workflows, medical device\nconnectivity, and AI-driven clinical insights, used in clinical research,\npatient management programs, and connected medical device ecosystems.\nFollowing closing, PONM operates as a wholly owned subsidiary of Nexalin\nTechnology, Inc., with its platform fully integrated into Nexalin’s HALO™\nClarity program.\n\nAbout GreenLight Ventures, LLC\n\nGreenLight Ventures is a North Carolina-based developer of digital health\ninfrastructure, partnering with healthcare technology companies to build\nsoftware systems that connect patients, clinicians, and connected medical\ndevices through secure, regulatory-grade platforms. Following the PONM\ntransaction, GreenLight is a long-term strategic partner and equity holder in\nNexalin Technology, Inc.\n\nFORWARD-LOOKING STATEMENTS\n\nThis press release contains “forward-looking statements” within the\nmeaning of Section 27A of the Securities Act of 1933, as amended, Section 21E\nof the Securities Exchange Act of 1934, as amended, and the Private Securities\nLitigation Reform Act of 1995 (the “PSLRA”). These forward-looking\nstatements relate to future events, future performance, or management’s\ncurrent expectations, beliefs, assumptions, plans, estimates, intentions, or\nprojections relating to the future, and are not guarantees of future\nperformance. Any statements that are not statements of historical fact, or\nthat refer to expectations, projections, or other characterizations of future\nevents or circumstances (including, without limitation, statements containing\nthe words “believes,” “expects,” “anticipates,” “plans,”\n“intends,” “will,” “may,” “could,” “should,” “would,”\n“designed to,” “positioned to,” “potential,” “targeted,”\n“seeking,” “continues,” “strategy,” “opportunity,”\n“estimates,” “projects,” “forecasts,” “predicts,”\n“outlook,” “guidance,” or similar expressions, or the negative of such\nterms), are forward-looking statements. These statements are based on\nNexalin’s current expectations, assumptions, and beliefs and are subject to\na number of risks and uncertainties that could cause actual results,\nperformance, or achievements to differ materially from those expressed or\nimplied by the forward-looking statements. Readers are cautioned not to place\nundue reliance on any forward-looking statements, which speak only as of the\ndate of this press release.\n\nForward-looking statements in this press release include, but are not limited\nto, statements regarding: the expected benefits, significance, strategic\nrationale, and potential implications of the PONM acquisition and the\nGreenLight strategic partnership; the integration, capabilities, operation,\ndeployment, and potential use of PONM, HALO™ Clarity, Nexalin NeuroCare™,\nand related AI-integrated remote patient monitoring, clinical-data capture,\nelectronic health record, virtual-clinic, analytics, cybersecurity,\nregulatory, quality assurance, and commercial-development capabilities; the\ndesign, enrollment, timing, progress, results, and potential outcomes of the\nHALO™ Clarity pivotal program and other future clinical trials; the\npotential for future development, regulatory progress (including any planned\nDe Novo FDA submission), and commercialization of the Company’s products and\ntechnology; the Company’s beliefs regarding its competitive position, market\nopportunity, value proposition, and anticipated patient, provider, clinical,\nand commercial benefits; the timing and issuance of transaction consideration;\nmanagement’s expectations regarding future regulatory submissions,\nclearances, approvals, and regulatory strategy; and the Company’s strategic\nplans, business prospects, financial and operating performance, and capital\nneeds. These forward-looking statements are not guarantees of future\nperformance and involve known and unknown risks, uncertainties, and other\nfactors that may cause the Company’s actual results, performance, or\nachievements to be materially different from any future results, performance,\nor achievements expressed or implied by such forward-looking statements. No\nassurance can be given that the anticipated benefits of the transaction or\nstrategic partnership will be realized, that future studies will be initiated\nor completed on a timely basis or at all, that the Company’s technology will\nreceive regulatory clearance or approval for any particular indication or on\nany anticipated timeline, or that the Company will be able to commercialize\nits products or technology.\n\nForward-looking statements are subject to numerous risks and uncertainties,\nmany of which are beyond the Company’s control. Such risks include, but are\nnot limited to: the Company’s ability to successfully integrate, maintain,\nsecure, validate, and scale PONM and related AI-integrated, data, software,\nand clinical-workflow systems; the ability to realize the anticipated benefits\nof the PONM acquisition and GreenLight strategic partnership; uncertainties\nregarding the design, enrollment, execution, timing, results, and completion\nof clinical trials, including the HALO™ Clarity pivotal program; the ability\nto obtain regulatory clearance or approval from the U.S. Food and Drug\nAdministration (the “FDA”) or other regulatory bodies, including with\nrespect to any planned De Novo submission; the sufficiency of clinical and\nnon-clinical data to support regulatory submissions; changes in FDA,\nhealthcare, data privacy, cybersecurity, and other applicable regulatory\nrequirements; the potential for adverse events, safety concerns, or product\nperformance issues; market acceptance of, and reimbursement for, the\nCompany’s products; the Company’s ability to protect and enforce its\nintellectual property rights; competition from existing and new treatment\nalternatives; the Company’s reliance on GreenLight, UCSD, third-party\nmanufacturers, suppliers, clinical investigators, technology vendors, and\nother third parties; the Company’s ability to secure adequate funding on\nacceptable terms to complete its planned clinical, regulatory, and commercial\nprograms; potential dilution or market effects from equity issuances and share\nprice volatility; and general economic, political, regulatory, industry, and\nmarket conditions. Additional risks and uncertainties that could cause actual\nresults to differ materially are described under the heading “Risk\nFactors” in the Company’s most recent Annual Report on Form 10-K for the\nyear ended December 31, 2025, and in the Company’s subsequent Quarterly\nReports on Form 10-Q, Current Reports on Form 8-K, and other filings the\nCompany makes from time to time with the U.S. Securities and Exchange\nCommission (the “SEC”). Copies of these filings are available free of\ncharge on the SEC’s website at www.sec.gov and on the Company’s investor\nrelations website. New risks and uncertainties emerge from time to time, and\nit is not possible for the Company to predict all such risks or to assess the\nimpact of all such risks on its business or the extent to which any risk, or\ncombination of risks, may cause actual results to differ materially from those\ncontained in any forward-looking statements.\n\nAll forward-looking statements in this press release are qualified in their\nentirety by this cautionary statement and the risk factors and other\ndisclosures referenced above, and speak only as of the date they are made.\nExcept as required by applicable law, the Company undertakes no obligation to\npublicly update or revise any forward-looking statement, whether as a result\nof new information, future events, changed circumstances, or otherwise, after\nthe date of this press release.\n\nContact:\n\nCrescendo Communications, LLC\nTel: (212) 671-1020\nEmail: NXL@crescendo-ir.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE5Prrnj","title":"Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial","author":"Globe Newswire","ticker":"NXL","created":"2026-05-19T12:30:00.365Z","tickers":["NXL"],"exchange":"NASDAQ","article_body":"Acquisition gives Nexalin control of AI-integrated remote patient-monitoring,\nclinical data-capture and virtual-care infrastructure already deployed at UCSD\n\nHOUSTON, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc.\n(https://www.globenewswire.com/Tracker?data=HF4Wy7GwqwKbBEYDet4v36q8CzvC_i2u9qmSx0gRP3JNhjHZN7NoWdxsKzJ_ZeJfQMx1iVUpULWj1Am2xNRUBiDtGuXABQqgW5FGO81otzw7NAqhES0Y-UpPS10DYzaCr5ii1vU0Zx9vg4rlLEg0KsQ7gf7Q4JLgG12z7u_6tGLlRiLGfKWPHhnaU5uLZ45YI9u3Q_2MD58Y3Flir6SEWFGPqUDVqx6HC05naOjMY_Iwcsz3ciMmH8DnFTIauQHbygx--iA2vjX_y-amLhB2w1WTzo6aszqokHOsrRAxIus=)\n( (Nasdaq: NXL) (“Nexalin” or the “Company”), the leader in\nnon-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain,\ntoday announced the closing of its acquisition of PONM, Inc. (“PONM”) from\nGreenLight Ventures, LLC (“GreenLight”). PONM is the digital health\nplatform supporting Nexalin’s HALO™ Clarity program and Nexalin\nNeuroCare™ virtual clinic.\n\nThrough the transaction, Nexalin has secured ownership of PONM and an\nexclusive license to the proprietary software features developed for the\nHALO™ program, including AI-integrated remote patient monitoring,\ntreatment-compliance data capture, electronic health record functionality,\nvirtual-clinic management, real-time clinical-data analysis and analytics\ncapabilities. The technology is already deployed at the University of\nCalifornia, San Diego (“UCSD”), where it supports HALO™ headset usage\ntracking, remote prescribing, physician oversight and clinical research\nworkflows.\n\nThe acquisition gives Nexalin greater control over a critical layer of its\nHALO™ Clarity ecosystem: the digital infrastructure that connects the\ndevice, the patient, the prescribing physician and the clinical-data workflow.\nNexalin believes this integrated device-plus-software model is important to\nthe Company’s planned pivotal trial, future regulatory strategy and\npotential commercial deployment of HALO™ Clarity as an at-home,\nphysician-supervised therapy. The platform is designed to use AI-enabled tools\nto support real-time data capture, treatment-adherence monitoring, protocol\ncompliance and physician oversight across clinical research and future\npatient-management workflows.\n\nAt UCSD, phases one through five of the Nexalin NeuroCare™ virtual clinic\nhave been deployed to support patient recruitment, AI-integrated monitoring\nand clinical-data workflows for Nexalin’s TBI/PTSD military study, and are\nbeing readied to support the Company’s planned 160-participant FDA pivotal\ntrial of HALO™ Clarity for moderate-to-severe insomnia, with enrollment\nexpected to begin in Q2 2026.\n\nIn connection with the transaction, GreenLight has become a meaningful equity\nholder in Nexalin, aligning the parties around the long-term success of\nHALO™ Clarity, Nexalin NeuroCare™ and the Company’s broader\nneurostimulation platform.\n\nAs part of the broader transaction structure, Nexalin and GreenLight have\nentered into a strategic partnership that provides Nexalin with continued\naccess to GreenLight’s product, engineering, quality assurance,\ncybersecurity, regulatory, behavioral-health and commercial-development\ncapabilities.\n\n“This acquisition gives Nexalin ownership of a critical part of the HALO™\nClarity ecosystem: the digital platform that connects the device, the patient,\nthe physician and the clinical-data workflow,” said Mark White, Chief\nExecutive Officer of Nexalin Technology. “The PONM platform is already\ndeployed at UCSD and supports the AI-integrated remote-monitoring,\nclinical-data capture and virtual-clinic capabilities we believe are essential\nto scaling HALO™ Clarity. By bringing this infrastructure under Nexalin\nownership, we are strengthening our ability to execute through pivotal trial\nactivities, planned FDA submission and potential commercial launch. We believe\ncombining HALO™ Clarity with AI-enabled data infrastructure can strengthen\ntreatment oversight, improve protocol adherence and create a scalable\nfoundation for future physician-supervised, at-home neurostimulation\nprograms.”\n\n“We believe the future of neurostimulation will be defined not only by the\ndevice itself, but by the software, data and physician-supervised care model\naround it,” continued Mr. White. “This transaction strengthens Nexalin’s\ncontrol over that full ecosystem and expands what we believe the Company can\nultimately offer to patients and providers seeking non-invasive treatment\nalternatives.”\n\n“GreenLight has spent years building digital infrastructure for\nnext-generation healthcare technologies, and HALO™ Clarity is exactly the\ntype of platform our work was designed to support,” said Peter Gratale,\nFounder of GreenLight Ventures. “With this transaction, Nexalin has the\nexclusive rights to the platform, while GreenLight remains aligned as both a\nlong-term partner and shareholder. Under our strategic partnership,\nGreenLight’s broader product, engineering, regulatory, clinical and\ncommercial capabilities will remain available to support HALO™ Clarity\nthrough pivotal trial execution, regulatory submission and potential\ncommercial launch.”\n\nTotal consideration for the transaction is $1.3 million, payable in shares of\nNexalin common stock issued in tranches over time at prices tied to\nNexalin’s market performance. Nexalin believes this structure aligns\nGreenLight’s economics with the long-term success of the HALO™ Clarity and\nNexalin NeuroCare™ programs.\n\nNexalin believes the transaction strengthens its ability to integrate device,\nsoftware, AI-enabled remote monitoring and clinical-data infrastructure under\na unified platform designed to support HALO™ Clarity through clinical\ndevelopment, regulatory submission and planned commercialization.\n\nAbout Nexalin Technology, Inc.\n\nNexalin designs and develops innovative neurostimulation products to uniquely\nhelp combat the ongoing global mental health epidemic. Nexalin’s medical\ndevices are non-invasive and undetectable to the human body. Nexalin believes\nits neurostimulation medical devices can penetrate structures deep in the\nmid-brain that are associated with mental health disorders, and that the\ndeeper-penetrating waveform in its next-generation devices, including the\nHALO™ Clarity, will generate enhanced patient response without adverse side\neffects. The Nexalin Gen-2 SYNC 15 milliamp neurostimulation device has been\napproved in China, Brazil, Oman, and Israel. Additional information is\navailable at www.nexalin.com.\n\nAbout PONM\n\nPONM is a digital health platform built to power next-generation healthcare\ntechnologies. Its software supports clinical data capture, remote patient\nmonitoring, electronic health records, telehealth workflows, medical device\nconnectivity, and AI-driven clinical insights, used in clinical research,\npatient management programs, and connected medical device ecosystems.\nFollowing closing, PONM operates as a wholly owned subsidiary of Nexalin\nTechnology, Inc., with its platform fully integrated into Nexalin’s HALO™\nClarity program.\n\nAbout GreenLight Ventures, LLC\n\nGreenLight Ventures is a North Carolina-based developer of digital health\ninfrastructure, partnering with healthcare technology companies to build\nsoftware systems that connect patients, clinicians, and connected medical\ndevices through secure, regulatory-grade platforms. Following the PONM\ntransaction, GreenLight is a long-term strategic partner and equity holder in\nNexalin Technology, Inc.\n\nFORWARD-LOOKING STATEMENTS\n\nThis press release contains “forward-looking statements” within the\nmeaning of Section 27A of the Securities Act of 1933, as amended, Section 21E\nof the Securities Exchange Act of 1934, as amended, and the Private Securities\nLitigation Reform Act of 1995 (the “PSLRA”). These forward-looking\nstatements relate to future events, future performance, or management’s\ncurrent expectations, beliefs, assumptions, plans, estimates, intentions, or\nprojections relating to the future, and are not guarantees of future\nperformance. Any statements that are not statements of historical fact, or\nthat refer to expectations, projections, or other characterizations of future\nevents or circumstances (including, without limitation, statements containing\nthe words “believes,” “expects,” “anticipates,” “plans,”\n“intends,” “will,” “may,” “could,” “should,” “would,”\n“designed to,” “positioned to,” “potential,” “targeted,”\n“seeking,” “continues,” “strategy,” “opportunity,”\n“estimates,” “projects,” “forecasts,” “predicts,”\n“outlook,” “guidance,” or similar expressions, or the negative of such\nterms), are forward-looking statements. These statements are based on\nNexalin’s current expectations, assumptions, and beliefs and are subject to\na number of risks and uncertainties that could cause actual results,\nperformance, or achievements to differ materially from those expressed or\nimplied by the forward-looking statements. Readers are cautioned not to place\nundue reliance on any forward-looking statements, which speak only as of the\ndate of this press release.\n\nForward-looking statements in this press release include, but are not limited\nto, statements regarding: the expected benefits, significance, strategic\nrationale, and potential implications of the PONM acquisition and the\nGreenLight strategic partnership; the integration, capabilities, operation,\ndeployment, and potential use of PONM, HALO™ Clarity, Nexalin NeuroCare™,\nand related AI-integrated remote patient monitoring, clinical-data capture,\nelectronic health record, virtual-clinic, analytics, cybersecurity,\nregulatory, quality assurance, and commercial-development capabilities; the\ndesign, enrollment, timing, progress, results, and potential outcomes of the\nHALO™ Clarity pivotal program and other future clinical trials; the\npotential for future development, regulatory progress (including any planned\nDe Novo FDA submission), and commercialization of the Company’s products and\ntechnology; the Company’s beliefs regarding its competitive position, market\nopportunity, value proposition, and anticipated patient, provider, clinical,\nand commercial benefits; the timing and issuance of transaction consideration;\nmanagement’s expectations regarding future regulatory submissions,\nclearances, approvals, and regulatory strategy; and the Company’s strategic\nplans, business prospects, financial and operating performance, and capital\nneeds. These forward-looking statements are not guarantees of future\nperformance and involve known and unknown risks, uncertainties, and other\nfactors that may cause the Company’s actual results, performance, or\nachievements to be materially different from any future results, performance,\nor achievements expressed or implied by such forward-looking statements. No\nassurance can be given that the anticipated benefits of the transaction or\nstrategic partnership will be realized, that future studies will be initiated\nor completed on a timely basis or at all, that the Company’s technology will\nreceive regulatory clearance or approval for any particular indication or on\nany anticipated timeline, or that the Company will be able to commercialize\nits products or technology.\n\nForward-looking statements are subject to numerous risks and uncertainties,\nmany of which are beyond the Company’s control. Such risks include, but are\nnot limited to: the Company’s ability to successfully integrate, maintain,\nsecure, validate, and scale PONM and related AI-integrated, data, software,\nand clinical-workflow systems; the ability to realize the anticipated benefits\nof the PONM acquisition and GreenLight strategic partnership; uncertainties\nregarding the design, enrollment, execution, timing, results, and completion\nof clinical trials, including the HALO™ Clarity pivotal program; the ability\nto obtain regulatory clearance or approval from the U.S. Food and Drug\nAdministration (the “FDA”) or other regulatory bodies, including with\nrespect to any planned De Novo submission; the sufficiency of clinical and\nnon-clinical data to support regulatory submissions; changes in FDA,\nhealthcare, data privacy, cybersecurity, and other applicable regulatory\nrequirements; the potential for adverse events, safety concerns, or product\nperformance issues; market acceptance of, and reimbursement for, the\nCompany’s products; the Company’s ability to protect and enforce its\nintellectual property rights; competition from existing and new treatment\nalternatives; the Company’s reliance on GreenLight, UCSD, third-party\nmanufacturers, suppliers, clinical investigators, technology vendors, and\nother third parties; the Company’s ability to secure adequate funding on\nacceptable terms to complete its planned clinical, regulatory, and commercial\nprograms; potential dilution or market effects from equity issuances and share\nprice volatility; and general economic, political, regulatory, industry, and\nmarket conditions. Additional risks and uncertainties that could cause actual\nresults to differ materially are described under the heading “Risk\nFactors” in the Company’s most recent Annual Report on Form 10-K for the\nyear ended December 31, 2025, and in the Company’s subsequent Quarterly\nReports on Form 10-Q, Current Reports on Form 8-K, and other filings the\nCompany makes from time to time with the U.S. Securities and Exchange\nCommission (the “SEC”). Copies of these filings are available free of\ncharge on the SEC’s website at www.sec.gov and on the Company’s investor\nrelations website. New risks and uncertainties emerge from time to time, and\nit is not possible for the Company to predict all such risks or to assess the\nimpact of all such risks on its business or the extent to which any risk, or\ncombination of risks, may cause actual results to differ materially from those\ncontained in any forward-looking statements.\n\nAll forward-looking statements in this press release are qualified in their\nentirety by this cautionary statement and the risk factors and other\ndisclosures referenced above, and speak only as of the date they are made.\nExcept as required by applicable law, the Company undertakes no obligation to\npublicly update or revise any forward-looking statement, whether as a result\nof new information, future events, changed circumstances, or otherwise, after\nthe date of this press release.\n\nContact:\n\nCrescendo Communications, LLC\nTel: (212) 671-1020\nEmail: NXL@crescendo-ir.com"},"type":"article","timestamp":"2026-05-19T12:30:00.430024763Z","server_sent_at_ms":1779193800430},"received_at":"2026-05-19T12:30:00.628Z","source_url":null},"analysis":{"id":"28618","press_release_id":"39177","analysis_json":{"industry":{"label":"Medical Devices","sector":"Health Care"},"redFlags":["Consideration paid entirely in stock, implying dilution","Pre-revenue company relying on third-party integration for pivotal trial execution"],"eventType":"m_and_a","narrative":"Nexalin has closed the acquisition of PONM, Inc., a digital health platform supporting its HALO Clarity and NeuroCare programs, from GreenLight Ventures for $1.3 million in stock.\n\nThe deal gives Nexalin exclusive ownership of the AI-integrated remote monitoring and clinical data infrastructure already deployed at UCSD, which is critical for its upcoming 160-participant pivotal trial for insomnia.\n\nGreenLight remains a strategic partner and equity holder, providing continued access to engineering and regulatory capabilities to support the pivotal trial and future FDA submission.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Nexalin secures full control of its digital health ecosystem ahead of pivotal trial, reducing third-party dependency."},"keyFigures":{"dealValueUsd":1300000,"customDimensions":{"pivotal_trial_participants":160,"pivotal_trial_enrollment_start":"Q2 2026"}},"quotedText":"This acquisition gives Nexalin ownership of a critical part of the HALO™ Clarity ecosystem: the digital platform that connects the device, the patient, the physician and the clinical-data workflow","namedEntities":{"people":[{"name":"Mark White","role":"CEO"},{"name":"Peter Gratale","role":"Founder of GreenLight Ventures"}],"products":["HALO Clarity","Nexalin NeuroCare","PONM","SYNC 15"],"companies":[{"name":"Nexalin Technology, Inc.","ticker":"NXL","relationship":"acquirer"},{"name":"PONM, Inc.","relationship":"target"},{"name":"GreenLight Ventures, LLC","relationship":"seller/partner"},{"name":"University of California, San Diego","relationship":"clinical site"}],"dollarAmounts":[{"amount":"$1.3 million","context":"total acquisition consideration"}]},"materialImpact":{"score":3,"reasoning":"Acquisition of a critical digital health platform (PONM) for $1.3M in stock strengthens the company's ecosystem for its upcoming pivotal trial. The deal is small in absolute dollar terms but strategically significant for regulatory and commercial execution. The stock-based consideration introduces minor dilution risk, but the strategic alignment with GreenLight and control over the HALO Clarity data infrastructure is a positive step for a pre-revenue biotech."},"tickerRelevance":{"others":[],"primary":"NXL"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":["partnership"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"strategic_milestone","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"event_type":"m_and_a","event_type_secondary":["partnership"],"sentiment":"bullish","material_impact_score":3,"narrative":"Nexalin has closed the acquisition of PONM, Inc., a digital health platform supporting its HALO Clarity and NeuroCare programs, from GreenLight Ventures for $1.3 million in stock.\n\nThe deal gives Nexalin exclusive ownership of the AI-integrated remote monitoring and clinical data infrastructure already deployed at UCSD, which is critical for its upcoming 160-participant pivotal trial for insomnia.\n\nGreenLight remains a strategic partner and equity holder, providing continued access to engineering and regulatory capabilities to support the pivotal trial and future FDA submission.","key_figures":{"dealValueUsd":1300000,"customDimensions":{"pivotal_trial_participants":160,"pivotal_trial_enrollment_start":"Q2 2026"}},"named_entities":{"people":[{"name":"Mark White","role":"CEO"},{"name":"Peter Gratale","role":"Founder of GreenLight Ventures"}],"products":["HALO Clarity","Nexalin NeuroCare","PONM","SYNC 15"],"companies":[{"name":"Nexalin Technology, Inc.","ticker":"NXL","relationship":"acquirer"},{"name":"PONM, Inc.","relationship":"target"},{"name":"GreenLight Ventures, LLC","relationship":"seller/partner"},{"name":"University of California, San Diego","relationship":"clinical site"}],"dollarAmounts":[{"amount":"$1.3 million","context":"total acquisition consideration"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-19T12:31:23.086Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"strategic_milestone","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"durationMs":22839,"modelName":"george-droid-qwen-72b"}}